Bristol-Myers Squibb & Co. (NYSE:BMY) on Monday released topline results from a phase 2 study evaluating Reblozyl for anemia in adults with Alpha (α)-Thalassemia, an inherited blood disorder characterized by reduced or absent production of globin chains, leading to insufficient hemoglobin, microcytic anemia and potential red blood cell destruction.

• Bristol-Myers Squibb stock is showing positive momentum. What’s ahead for BMY stock?

The study met its primary endpoints, showing a statistically significant increase in hemoglobin levels for non-transfusion-dependent patients and a decrease in red blood cell transfusion burden for transfusion-dependent patients.

The study also met all key secondary endpoints. Safety findings were consistent with the known profile of Reblozyl in thalassemia.

The results are expected to be presented at an upcoming medical ...